LifeMD, Inc. (LFMD)

Over the past six months, LifeMD's stock has been influenced by several events. In January 2026, LifeMD closed a $50 million revolving credit facility with Citizens Bank, N.A. and expanded its collaboration with Novo Nordisk to offer the Wegovy® Pill. In December 2025, a quarterly dividend was declared on its Series A Cumulative Perpetual Preferred Stock. November 2025 saw the release of positive Third Quarter results and recognition by Deloitte Technology Fast 500™ and TIME's America's Growth Leaders of 2026. The company divested its majority stake in WorkSimpli in late 2025. Analysts noted a potential upside for the stock in October 2025. LifeMD participated in several investment conferences in September 2025 and reported its Second Quarter 2025 results in August 2025. In July 2025, the company announced the sale of its majority ownership interest in WorkSimpli. The share price as of January 2, 2026, was $3.49, representing a decline of 39.62% from January 6, 2025.

The provided search results do not explicitly detail demand seasonality for LifeMD, Inc.'s products and services. However, the company operates in the telehealth and digital health market, which has shown growing demand for virtual and telehealth services, particularly for chronic condition management and specialized care. The introduction of new offerings like GLP-1s for weight management and expansion into behavioral and women's health suggest a strategy to capture broader market trends and potentially stabilize demand across different health needs.

LifeMD, Inc. is a direct-to-patient telehealth company operating in the Healthcare sector, focusing on Health Services, Health Information Services, Medical/Nursing Services, and Medical - Pharmaceuticals. The company provides accessible virtual healthcare through its telehealth platform, featuring brands like RexMD for men's health, ShapiroMD for hair loss, Cleared for allergy and asthma, LifeMD PC for virtual primary care, and GLP-1 for weight management. LifeMD divested its majority stake in WorkSimpli in late 2025 to focus on telehealth and pharmacy services.

LifeMD, Inc. primarily operates and connects consumers to healthcare professionals for medical care in the United States.

LifeMD has received positive recognition, being named to the 2025 Deloitte Technology Fast 500™ and TIME's America's Growth Leaders of 2026. However, there was also a lawsuit against LifeMD over alleged concealment of cost and refund issues in key segments.

LifeMD, Inc. has a mix of institutional, insider, and retail ownership. As of August 2025, institutional investors held 57.14% of the company's shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Renaissance Technologies Llc, Nuveen, LLC, and State Street Corp. Individual insiders also maintain substantial stakes; CEO Justin Schreiber owned 2,703,715 shares as of June 2025. Approximately 58.77% of LifeMD (LFMD) stock is held by retail investors.